These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 30273596)

  • 1. Notch Signaling Activity Determines Uptake and Biological Effect of Imatinib in Systemic Sclerosis Dermal Fibroblasts.
    Harrach S; Barz V; Pap T; Pavenstädt H; Schlatter E; Edemir B; Distler J; Ciarimboli G; Bertrand J
    J Invest Dermatol; 2019 Feb; 139(2):439-447. PubMed ID: 30273596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.
    Pannu J; Asano Y; Nakerakanti S; Smith E; Jablonska S; Blaszczyk M; ten Dijke P; Trojanowska M
    Arthritis Rheum; 2008 Aug; 58(8):2528-37. PubMed ID: 18668566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
    Blanc Mettral J; Faller N; Cruchon S; Sottas L; Buclin T; Schild L; Choong E; Nahimana A; Decosterd LA
    Drug Metab Lett; 2019; 13(2):102-110. PubMed ID: 30734690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.
    Harrach S; Schmidt-Lauber C; Pap T; Pavenstädt H; Schlatter E; Schmidt E; Berdel WE; Schulze U; Edemir B; Jeromin S; Haferlach T; Ciarimboli G; Bertrand J
    Blood Cancer J; 2016 Sep; 6(9):e470. PubMed ID: 27635733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro.
    Hinchcliff M; Huang CC; Ishida W; Fang F; Lee J; Jafari N; Wilkes M; Bhattacharyya S; Leof E; Varga J
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S86-96. PubMed ID: 22691216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
    Distler JH; Jüngel A; Huber LC; Schulze-Horsel U; Zwerina J; Gay RE; Michel BA; Hauser T; Schett G; Gay S; Distler O
    Arthritis Rheum; 2007 Jan; 56(1):311-22. PubMed ID: 17195235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis.
    Akhmetshina A; Venalis P; Dees C; Busch N; Zwerina J; Schett G; Distler O; Distler JH
    Arthritis Rheum; 2009 Jan; 60(1):219-24. PubMed ID: 19116940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts.
    Bujor AM; Asano Y; Haines P; Lafyatis R; Trojanowska M
    Arthritis Rheum; 2011 Jun; 63(6):1729-37. PubMed ID: 21321929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts.
    Chen Y; Leask A; Abraham DJ; Pala D; Shiwen X; Khan K; Liu S; Carter DE; Wilcox-Adelman S; Goetinck P; Denton CP; Black CM; Pitsillides AA; Sarraf CE; Eastwood M
    Arthritis Rheum; 2008 Feb; 58(2):577-85. PubMed ID: 18240216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis.
    Reich N; Maurer B; Akhmetshina A; Venalis P; Dees C; Zerr P; Palumbo K; Zwerina J; Nevskaya T; Gay S; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2010 Jan; 62(1):280-90. PubMed ID: 20039427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis.
    Dees C; Tomcik M; Zerr P; Akhmetshina A; Horn A; Palumbo K; Beyer C; Zwerina J; Distler O; Schett G; Distler JH
    Ann Rheum Dis; 2011 Jul; 70(7):1304-10. PubMed ID: 21450749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH.
    Wasson CW; Abignano G; Hermes H; Malaab M; Ross RL; Jimenez SA; Chang HY; Feghali-Bostwick CA; Del Galdo F
    Ann Rheum Dis; 2020 Apr; 79(4):507-517. PubMed ID: 32041748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis.
    Ishibuchi H; Abe M; Yokoyama Y; Ishikawa O
    Exp Dermatol; 2010 Aug; 19(8):e111-6. PubMed ID: 20653770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
    Karimizadeh E; Motamed N; Mahmoudi M; Jafarinejad-Farsangi S; Jamshidi A; Faridani H; Gharibdoost F
    Arch Dermatol Res; 2015 Mar; 307(2):135-42. PubMed ID: 25527259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discoidin domain receptor 2-microRNA 196a-mediated negative feedback against excess type I collagen expression is impaired in scleroderma dermal fibroblasts.
    Makino K; Jinnin M; Aoi J; Hirano A; Kajihara I; Makino T; Sakai K; Fukushima S; Inoue Y; Ihn H
    J Invest Dermatol; 2013 Jan; 133(1):110-9. PubMed ID: 22832484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritis.
    Schmidt-Lauber C; Harrach S; Pap T; Fischer M; Victor M; Heitzmann M; Hansen U; Fobker M; Brand SM; Sindic A; Pavenstädt H; Edemir B; Schlatter E; Bertrand J; Ciarimboli G
    PLoS One; 2012; 7(12):e52247. PubMed ID: 23284953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical study.
    Soria A; Cario-André M; Lepreux S; Rezvani HR; Pasquet JM; Pain C; Schaeverbeke T; Mahon FX; Taïeb A
    Dermatology; 2008; 216(2):109-17. PubMed ID: 18216472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities.
    Iwayama T; Olson LE
    Curr Rheumatol Rep; 2013 Feb; 15(2):304. PubMed ID: 23307576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1.
    Omote S; Matsuoka N; Arakawa H; Nakanishi T; Tamai I
    Sci Rep; 2018 Jun; 8(1):9237. PubMed ID: 29915248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
    Denton CP; Ong VH; Xu S; Chen-Harris H; Modrusan Z; Lafyatis R; Khanna D; Jahreis A; Siegel J; Sornasse T
    Ann Rheum Dis; 2018 Sep; 77(9):1362-1371. PubMed ID: 29853453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.